La FDA accorde une autorisation d’urgence pour le traitement expérimental par anticorps administré au président

The latest coronavirus news from Canada and around the world Saturday. This file will be updated throughout the day. Web links to longer stories if available.
8:59 p.m.: Duke University is sometimes referred to as a pretty good knock-off of fancier schools farther north. But while those ivy-clad universities with smart students, prestigious medical schools and big endowments stayed closed this fall, Duke invited its freshmen, sophomores, some upperclassmen and all of its graduate students to its Durham, North Carolina, campus for largely in-person classes.
Now, it’s schooling those sniffier schools on how to reopen safely.

https://medium.com/wahyu-hidayat/la-fda-accorde-une-autorisation-durgence-pour-le-traitement-exp%C3%A9rimental-par-anticorps-administr%C3%A9-ebbde4fc5ede

Starting Aug. 2 and continuing up to this week, when the Duke campus made a pre-planned reversion to online classes for the remainder of the semester, the university implemented a rigorous testing, tracking and surveillance program for more than 10,000 students. And it has carried out, on a grand scale, an innovative scheme — called pooled testing — that can stretch limited testing resources without forfeiting accuracy or resolution.
For Duke’s returning students, the result has been a relatively safe and almost normal return to learning, at a time when other colleges and universities either shuttered their campuses or ignited community outbreaks as they reopened with scant measures in place to detect or isolate infected students.
8:57 p.m.: The Food and Drug Administration has granted emergency authorization for the experimental antibody treatment given to President Donald Trump shortly after he was diagnosed with COVID-19, giving doctors another option to treat COVID-19 patients as cases across the country continue to rise.
The treatment, made by the biotech company Regeneron, is a cocktail of two powerful antibodies that have shown promise in early studies at keeping the infection in check, reducing medical visits in patients who get the drug early in the course of their disease. A similar treatment, made by Eli Lilly, was given emergency approval earlier this month.
The emergency authorization for Regeneron’s drug is limited in scope: It is for people who have tested positive for the coronavirus and who are at high risk for developing severe COVID-19. Evidence so far suggests that antibody treatments work best early in the course of the disease. Like Eli Lilly’s treatment, Regeneron’s is not authorized for use in people who are hospitalized or who need oxygen.